KZR vs LLY · $53.9M cap vs P/E 39, rev $22.97B
Kezar Life Sciences Inc (KZR) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Kezar Life Sciences Inc (KZR) is a biotechnology company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David A. Ricks.
Latest reported KZR revenue for 2024-12-31 was $0. Net income was -$83.7M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. KZR currently screens at market cap $53.9M.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
KZR currently screens at market cap $53.9M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the KZR and LLY stock pages for the full models.
Not investment advice.